Prevention of Platelet Deposition and Thrombus Formationon Hemodialysis Membranes: A Double-Blind Randomized Trial of Aspirin and Dipyridamole
Article first published online: 12 NOV 2008
© 1984 International Society for Artificial Organs
Volume 8, Issue 1, pages 57–61, February 1984
How to Cite
Salter, M. C. P., Crow, M. J., Donaldson, D. R., Roberts, T. G., Rajah, S. M. and Davison, A. M. (1984), Prevention of Platelet Deposition and Thrombus Formationon Hemodialysis Membranes: A Double-Blind Randomized Trial of Aspirin and Dipyridamole. Artificial Organs, 8: 57–61. doi: 10.1111/j.1525-1594.1984.tb04244.x
- Issue published online: 12 NOV 2008
- Article first published online: 12 NOV 2008
- Received October 1982; revised January 1983.
- Cuprophan membranes;
- Thrombus formation;
Abstract: A double-blind crossover study comparing low-dose aspirin (ASA) and dipyridamole (DPM) (100 mg ASA+75 mg DPM, t.d.s.), high-dose ASA and DPM (300 mg ASA+75 mg DPM, t.d.s.), and placebo on platelet deposition and thrombus formation on hemodialysis membranes was undertaken in 17 long-term dialysis patients. The high-dose combination significantly reduced the fall in platelet count during dialysis and also significantly increased postdialysis heparin concentrations. Scanning electron microscopy of the Cuprophan membranes showed a reduction in platelet desposition and fibrin formation during both treatment schedules, but this was most marked with the high-dose combination. The results of this study indicate that there is a graded response to combined ASA-DPM treatment and that this can significantly reduce platelet consumption and contact activation of fibrin during hemodialysis with Cuprophan membranes.